tbuckley/cabot-search huggingface dataset:
AB0451 Rivaroxaban versus warfarin as secondary thromboprophylaxis in patients with antiphospholipid syndrome protocol: a randomized, multicentre, open-label, clinical trial
Authors: J Cortés-Hernández, L Saez-Comet, M Perez-Conesa, A Riera Mestre, A Castro-Salomo, S Parra, J Cuquet-Pedragosa, V Ortiz-Santamaria, M Mauri-Plana, P Suñe, J Ordi-Ros
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Long-term anticoagulation is widely used for secondary thromboprophylaxis in the antiphospholipid syndrome (APS) due to the high risk of recurrent events. Currently anticoagulation with vitamin K antagonists (VKAs) is the standard of care but have unpredictable pharmacodynamic properties that requiere monitoring for dose adjustment. Rivaroxaban, an orally active direct factor Xa inhibitor, has been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism and non valvular atrial fibrillation in major RCTs. No studies had been published in APS. <h3>Objectives</h3> To investigate the efficacy and safety of rivaroxaban in preventing recurrent thrombosis in patients with APS compared with warfarin. <h3>Methods</h3> This is a phase 3 randomized, multicenter, non-inferiority open-label RCT. 190 eligible APS patients with arterial or venous thrombotic history receiving warfarin will be stratified according the presence of SLE and venous/arterial thrombotic history and randomized (1:1) either to continue warfarin (standard of care, normalized ratio (INR) 2–3 or 2.5 to 3.5 in those with recurrent thrombotic episodes) or to switch to rivaroxaban (20 mg/day). The primary efficacy outcome is the development of any thrombotic event during the study period. Secondary efficacy outcomes include time to thrombosis, type of thrombosis (arterial or venous), overall causes of death, evaluation of a prognostic biomarker panel of recurrent thrombosis. The primary safety outcome will be major bleeding. Secondary safety outcomes include any adverse event and minor bleeding. The study has 3 years follow-up. First patient was included in March 2013 (EUDRA-CT:2010–019764–36). <h3>Conclusions</h3> If the study demonstrates a non-inferior anticoagulant effect compared with warfarin, this would provide sufficient supporting evidence to make rivaroxaban a standard of care for the treatment of patients with APS with previous thrombotic history. <h3>Disclosure of Interest</h3> None declared
Reply
Authors: Cormac McCarthy, Emer P. Reeves, Carl Orr, Ursula Fearon, Douglas J. Veale, Noel G. McElvaney
Journal: Arthritis & Rheumatology (2017)

We thank Drs Hutchinson and Eggleton for their interest in our report and for raising some interesting points. While we believe there is some merit in the issues they raise, we do not believe these invalidate the data we have presented or the conclusions we made in our initial report.

This article is protected by copyright. All rights reserved.
特定のインフラマソーム遺伝子モジュールの発現によって,高齢者は二極的な臨床的・免疫的状態に分類される
Authors: Furman David, Davis Mark M, Chang Junlei, Kuo Calvin J, Lartigue Lydia, Bolen Christopher R, Gaudilliere Brice, Ganio Edward A, Fragiadakis Gabriela K, Spitzer Matthew H, Nolan Garry P, Haddad Francois, Douchet Isabelle, Daburon Sophie, Moreau Jean‐Francois, Blanco Patrick, Dechanet‐Merville Julie, Faustin Benjamin, Dekker Cornelia L, Jojic Vladimir
Journal: Nature Medicine (2017)
A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal
Authors: S. Weidinger, H. Baurecht, J. Schmitt
Journal: British Journal of Dermatology (2017)

The PETITE study (Sigurgeirsson et al.) aimed to compare safety and efficacy of pimecrolimus 1% cream (PIM) and low-to-medium-potency topical corticosteroids (TCS) in children with mild-to-moderate atopic dermatitis (AD).Participants of this 5-year drug-company sponsored multicentre, open-label, parallel-group trial were recruited between April 2004 and October 2005. No details are reported regarding the study sites.Infants aged ≥ 3 to < 12 months with mild-to-moderate AD were randomly assigned in a 1 : 1 ratio to receive either PIM or a low- or medium-potency TCS cream/ointment for 5 years. No information on specific TCS products used was provided. The topical treatment was applied twice daily 'until complete AD clearance or for as long as allowed by the label of the specific TCS', and was reinitiated at the occurrence of first signs and symptoms of AD flares. In the PIM group, exacerbations not controlled by PIM were treated with short-term TCSs.Adverse events (AEs) and serious AEs (SAEs) were recorded 'during clinic visits'. In a proportion of the patients, various immunological assessments including antibody titres to common vaccine antigens, immunoglobulin levels, B and T lymphocyte cell counts, and T-cell proliferation tests were performed. The children's growth was assessed by measuring height and weight. AD severity was measured using the Investigator Global Assessment (IGA) score and the percentage of the total body surface area affected. No specific information was provided on the number and scheduling of study visits. Primary outcomes were the incidence of AEs 'of primary clinical interest' and those with a crude incidence of ≥ 5% in either treatment group. Secondary outcome was 'long-term efficacy' defined as IGA ≤ 1 at week 3 and year 5.Patients in the PIM group experienced significantly more AEs [bronchitis (P = 0·02), infected eczema (P ≤ 0·001), impetigo (P = 0·045), nasopharyngitis (P = 0·04)]. No significant differences were seen for the other AEs. The overall incidence of SAEs was slightly higher for PIM (20·5% vs. 17·3%; P = 0·046). The proportion of participants with IGA ≤ 1 at year 5 was 88·7% for PIM and 92·3% for TCS, a success rate difference of 3·6% (95% confidence interval 0·8-6·4) favouring TCS.Sigurgeirsson et al. conclude that the long-term management of mild-to-moderate AD in children with both TCS and PIM is safe, and that PIM has similar efficacy to TCS. Further, they conclude that their data support the use of PIM as a first-line treatment of mild-to-moderate AD in children.
Critical role of mammalian target of rapamycin for IL-10 dendritic cell induction by a flagellin A conjugate in preventing allergic sensitization
Authors: Stefan Schülke, Anna-Helena Fiedler, Ann-Christine Junker, Adam Flaczyk, Sonja Wolfheimer, Andrea Wangorsch, Anke Heinz, Hendrik Beckert, Birgit Nagl, Barbara Bohle, Stefan Vieths, Masako Toda, Stephan Scheurer
Journal: Journal of Allergy and Clinical Immunology (2017)
Abstract 92: Platelet Derived Growth Factor Receptor Alpha Signaling is Required for Cardiac Fibroblast Survival and Proliferation
Authors: Malina J Ivey, Michelle D Tallquist
Journal: Circulation Research (2016)

Cardiac fibrosis contributes significantly to heart disease and is a hallmark of decreased cardiac function. Currently, there are no treatments that attenuate fibrosis, but identification of signaling pathways required for fibroblast function would provide some potential targets. PDGFRα is a receptor tyrosine kinase that is required for fibroblast formation in the developing heart, and preliminary data indicates that it is also required for maintenance of resident fibroblasts and expansion of activated fibroblasts after injury. Preliminary experiments demonstrate that loss of PDGFRα expression in adult cardiac fibroblasts results in 50% reduction in the number of the resident fibroblasts by 4 days after gene deletion. This was further validated using an independent fibroblast marker, collagen1a1GFP. Based on the low basal level of fibroblast proliferation, we hypothesize that PDGFRα signaling is essential for fibroblast survival and that fibroblasts undergo rapid turnover in the absence of PDGFRα signaling. Future studies will determine the exact mechanism of this loss. We have also begun to elucidate which PDGFRα downstream signals promote fibroblast maintenance. Using a PDGFRα-dependent-PI3K-deficient mouse model, preliminary data indicates that PDGFRα-dependent PI3K signaling is essential for cell survival. We are also investigating the role of PDGFRα signaling after myocardial infarction. Using recently described genetic tools to follow fibroblasts after injury, we have determined that fibroblasts reach their peak of proliferation within a week after permanent left anterior descending artery ligation. This injury-induced proliferation is reduced by 50% after deletion of PDGFRα. Therefore, we have demonstrated that PDGFRα has a role in fibroblast maintenance in the healthy heart, as well as a role in fibroblast proliferation after injury. Our studies will continue to illuminate additional roles for PDGFRα in the fibroblast, as well as the implications of fibroblast loss on other cell types and overall heart function.
ペプチド酸化状態の実時間速度論的解析のためのウイルスDNAパッケージングモーターのチャンネル【Powered by NICT】
Authors: Wang Shaoying, Zhou Zhi, Zhao Zhengyi, Zhang Hui, Haque Farzin, Guo Peixuan
Journal: Biomaterials (2017)
[Correspondence] A manually curated functional annotation of the human X chromosome
Authors: H.C. Harsha, Shubha Suresh, Ramars Amanchy, Nandan Deshpande, K. Shanker, A.J. Yatish, Babylakshmi Muthusamy, B.M. Vrushabendra, B.P. Rashmi, K.N. Chandrika, N. Padma, Salil Sharma, Jose L. Badano, Ramya, Shivashankar H. Nagaraj, Suraj Peri, Dipanwita Roy Choudhury, M.P. Kavitha, R. Saravana, Vidya Niranjan, T.K.B. Gandhi, Neelanjana Ghosh, Sreenath Chandran, Minal Menezes, Mary Joy, S. Sujatha Mohan, Nicholas Katsanis, Krishna S. Deshpande, Chaerkady Raghothama, C.K. Prasad, Akhilesh Pandey
Journal: Nature Genetics (2005)
Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication By CD123-Specific Chimeric Antigen Receptor T Cells
Authors: Aaron E Foster, MyLinh Duong, An Lu, Peter Chang, Aruna Mahendravada, Nicholas Shinners, Kevin M Slawin, J. Henri Bayle, David M Spencer
Journal: Blood (2016)
増強photothermal/chemo治療のための「Nanoheater」ミトコンドリア標的化【Powered by NICT】
Authors: Chen Si, Lei Qi, Qiu Wen-Xiu, Liu Li-Han, Zheng Di-Wei, Fan Jin-Xuan, Rong Lei, Sun Yun-Xia, Zhang Xian-Zheng
Journal: Biomaterials (2017)
Peripheral donor leukocytes prolong survival of rat renal allografts
Authors: Marina Noris, Nadia Azzollini, Marilena Mister, Angela Pezzotta, Giampiero Piccinini, Federica Casiraghi, Daniela Cugini, Norberto Perico, Silvia Orisio, Giuseppe Remuzzi
Journal: Kidney International (1999)
Pesticide Use and Age-Related Macular Degeneration in the Agricultural Health Study
Authors: Martha P. Montgomery, Eric Postel, David M. Umbach, Marie Richards, Mary Watson, Aaron Blair, Honglei Chen, Dale P. Sandler, Silke Schmidt, Freya Kamel
Journal: Environmental Health Perspectives (2017)

Age-related macular degeneration (AMD) is a leading cause of blindness in developed countries. Few studies have investigated its relationship to environmental neurotoxicants. In previous cross-sectional studies, we found an association between pesticide use and self-reported retinal degeneration.We evaluated the association of pesticide use with physician-confirmed incident AMD.The Agricultural Health Study (AHS) is a prospective cohort of pesticide applicators and their spouses enrolled from 1993-1997 in Iowa and North Carolina. Cohort members reported lifetime use of 50 specific pesticides at enrollment. Self-reports of incident AMD during follow-up through 2007 were confirmed by reports from participants' physicians and by independent evaluation of retinal photographs provided by the physicians. Confirmed cases (n=161) were compared with AHS cohort members without AMD (n=39,108). We estimated odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regression with adjustment for age, gender, and smoking.AMD was associated with ever use of organochlorine [OR=2.7 (95% CI: 1.8, 4.0)] and organophosphate [OR=2.0 (95% CI: 1.3, 3.0)] insecticides and phenoxyacetate herbicides [OR=1.9 (95% CI: 1.2, 2.8)]. Specific pesticides consistently associated with AMD included chlordane, dichlorodiphenyltrichloroethane (DDT), malathion, and captan; others with notable but slightly less consistent associations were heptachlor, diazinon, phorate, 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), and 2,4-dichlorophenoxyacetic acid (2,4-D). Results were similar for men and women. Some specific pesticides were associated with both early- and late-stage AMD, but others were associated with only one stage.Exposures to specific pesticides may be modifiable risk factors for AMD. https://doi.org/10.1289/EHP793.
NUCLEAR FACTOR-kB (NF-kB) PREDICTS OUTCOME IN LOCALLY ADVANCED RECTAL CANCER PATIENTS RECEIVING RADIO-CHEMOTHERAPY
Authors: R Berardi, I Bearzi, A Mandolesi, Azzurra Onofri, G Mantello, E Maccarone, M Scartozzi, C Pierantoni, T Biscotti, C Marmorale, A Fianchini, Sstefano Cascinu
Journal: Annals of Oncology (2008)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Authors: Marie D. Gerhard-Herman, Heather L. Gornik, Coletta Barrett, Neal R. Barshes, Matthew A. Corriere, Douglas E. Drachman, Lee A. Fleisher, Francis Gerry R. Fowkes, Naomi M. Hamburg, Scott Kinlay, Robert Lookstein, Sanjay Misra, Leila Mureebe, Jeffrey W. Olin, Rajan A.G. Patel, Judith G. Regensteiner, Andres Schanzer, Mehdi H. Shishehbor, Kerry J. Stewart, Diane Treat-Jacobson, M. Eileen Walsh
Journal: Circulation (2016)
高分子ナノ粒子は腫瘍微小環境におけるM2M1への表現型からのマクロファージ反転を促進する【Powered by NICT】
Authors: Wang Yi, Lin Yao-Xin, Qiao Sheng-Lin, An Hong-Wei, Ma Yang, Qiao Zeng-Ying, R P J Rajapaksha Yeshan, Wang Hao
Journal: Biomaterials (2017)
Sharing and caring for better health
Authors: Fiona Godlee
Journal: BMJ (2017)

At your last medical scientific conference were you encouraged to tweet? And would you have been surprised if the organisers had asked you not to? Delegates at the American Diabetes Association scientific meeting in June found themselves in that position, being asked not to share photographs of presented slides through social media. As Dara Mohammadi explains (doi:10.1136/bmj.j3966), many delegates turned to Twitter to question the ADA’s draconian approach—more indeed than had been tweeting the conference proceedings.

The episode raises questions about …
Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW
Authors: Clare M. Adams, Ramkrishna Mitra, Jerald Z. Gong, Christine M. Eischen
Journal: Clinical Cancer Research (2017)

Abstract Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. To gain insight into the contribution of BCLW to B-cell lymphomas and its potential to confer resistance to BCL2 inhibitors, we investigated the expression of BCLW and the other antiapoptotic BCL2 family members in six different B-cell lymphomas. Experimental Design: We performed a large-scale gene expression analysis of datasets comprising approximately 2,300 lymphoma patient samples, including non-Hodgkin and Hodgkin lymphomas as well as indolent and aggressive lymphomas. Data were validated experimentally with qRT-PCR and IHC. Results: We report BCLW is significantly overexpressed in aggressive and indolent lymphomas, including DLBCL, Burkitt, follicular, mantle cell, marginal zone, and Hodgkin lymphomas. Notably, BCLW was preferentially overexpressed over that of BCL2 and negatively correlated with BCL2 in specific lymphomas. Unexpectedly, BCLW was overexpressed as frequently as BCL2 in follicular lymphoma. Evaluation of all five antiapoptotic BCL2 family members in six types of B-cell lymphoma revealed that BCL2, BCLW, and BCLX were consistently overexpressed, whereas MCL1 and A1 were not. In addition, individual lymphomas frequently overexpressed more than one antiapoptotic BCL2 family member. Conclusions: Our comprehensive analysis indicates B-cell lymphomas commonly select for BCLW overexpression in combination with or instead of other antiapoptotic BCL2 family members. Our results suggest BCLW may be equally as important in lymphomagenesis as BCL2 and that targeting BCLW in lymphomas should be considered. Clin Cancer Res; 23(22); 7119–29. ©2017 AACR.
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Authors: Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass, Nicole R. McMillian
Journal: Journal of the National Comprehensive Cancer Network (2017)

Many cancer survivors experience menopausal symptoms, including female survivors taking aromatase inhibitors or with a history of oophorectomy or chemotherapy, and male survivors who received or are receiving androgen-ablative therapies. Sexual dysfunction is also common in cancer survivors. Sexual dysfunction and menopause-related symptoms can increase distress and have a significant negative impact on quality of life. This portion of the NCCN Guidelines for Survivorship provide recommendations for screening, evaluation, and treatment of sexual dysfunction and menopausal symptoms to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period.
A Method for Identifying Prevalent Chemical Combinations in the U.S. Population
Authors: Dustin F. Kapraun, John F. Wambaugh, Caroline L. Ring, Rogelio Tornero-Velez, R. Woodrow Setzer
Journal: Environmental Health Perspectives (2017)

Background: Through the food and water they ingest, the air they breathe, and the consumer products with which they interact at home and at work, humans are exposed to tens of thousands of chemicals, many of which have not been evaluated to determine their potential toxicities. Furthermore, while current chemical testing tends to focus on individual chemicals, the exposures that people actually experience involve mixtures of chemicals. Unfortunately, the number of mixtures that can be formed from the thousands of environmental chemicals is enormous, and testing all of them would be impossible. Objectives: We seek to develop and demonstrate a method for identifying those mixtures that are most prevalent in humans. Methods: We applied frequent itemset mining, a technique traditionally used for market basket analysis, to biomonitoring data from the 2009–2010 cycle of the continuous National Health and Nutrition Examination Survey (NHANES) to identify combinations of chemicals that frequently co-occur in people. Results: We identified 90 chemical combinations consisting of relatively few chemicals that occur in at least 30% of the U.S. population, as well as three supercombinations consisting of relatively many chemicals that occur in a small but nonnegligible proportion of the U.S. population. Conclusions: We demonstrated how FIM can be used in conjunction with biomonitoring data to narrow a large number of possible chemical combinations down to a smaller set of prevalent chemical combinations. https://doi.org/10.1289/EHP1265
Wild-type ferroportin is not impeded in maturation, cell surface expression or iron export function by mutant ferroportin, and bio-luminescence resonance energy transfer (BRET) experiments indicate monomeric form in cell membranes
Authors: L M Schimanski, H Drakesmith, C Talbot, K Horne, James, E Sweetland, J M Bastin, D Cowley, S J Davis, Townsend Arm.
Journal: American Journal of Hematology (2007)
Sialic acid–binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin–dependent function in human eosinophils
Authors: Daniela J. Carroll, Jeremy A. O'Sullivan, David B. Nix, Yun Cao, Michael Tiemeyer, Bruce S. Bochner
Journal: Journal of Allergy and Clinical Immunology (2017)
Validity of Surrogate End Points for Prostate Cancer—Reply
Authors: Trevor J. Royce, Ming-Hui Chen, Anthony V. D’Amico
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Authors: Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier F. Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, David Hogg, John Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Ivan Marquez-Rodas, Massimo Guidoboni, Grant McArthur, Celeste Lebbé, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey Sosman, Michael A. Postow, Margaret K. Callahan, Dana Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin
Journal: New England Journal of Medicine (2017)

Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial.